Xenon (XENE) Stock Forecast & Price Target

Compare

385 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

XENE Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Xenon

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

XENE Stock 12 Month Forecast

Average Price Target

$55.00

▲(39.06% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Xenon in the last 3 months. The average price target is $55.00 with a high forecast of $65.00 and a low forecast of $48.00. The average price target represents a 39.06% change from the last price of $39.55.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"29":"$29","66":"$66","38.25":"$38.3","47.5":"$47.5","56.75":"$56.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$48.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[29,38.25,47.5,56.75,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.12,41.11076923076923,43.10153846153846,45.09230769230769,47.08307692307692,49.073846153846155,51.06461538461538,53.05538461538461,55.04615384615384,57.036923076923074,59.027692307692305,61.01846153846154,63.00923076923077,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.12,40.34153846153846,41.56307692307692,42.784615384615385,44.00615384615384,45.22769230769231,46.449230769230766,47.67076923076923,48.89230769230769,50.113846153846154,51.33538461538461,52.55692307692308,53.77846153846154,{"y":55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.12,39.80307692307692,40.48615384615385,41.169230769230765,41.85230769230769,42.535384615384615,43.21846153846154,43.90153846153846,44.58461538461538,45.26769230769231,45.95076923076923,46.63384615384615,47.316923076923075,{"y":48,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.34,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.38,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.69,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.12,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.2,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.02,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.64,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.07,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$65.00

Average Price Target$55.00

Lowest Price Target$48.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Myles Minter

William Blair

―

Buy

―

Reiterated

10/07/25

William Blair Reaffirms Their Buy Rating on Xenon (XENE)

Paul Matteis

Stifel Nicolaus

$60

Buy

51.71%

Upside

Reiterated

10/07/25

Stifel Nicolaus Keeps Their Buy Rating on Xenon (XENE)

Andrew Tsai

Jefferies

$65

Buy

64.35%

Upside

Reiterated

10/07/25

Xenon (XENE) Receives a Buy from Jefferies

Rudy Li

Chardan Capital

$55

Buy

39.06%

Upside

Reiterated

10/07/25

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (NASDAQ: BMEA), Xenon (NASDAQ: XENE) and Arcus Biosciences (NYSE: RCUS)We reiterate our Buy rating and $55 PT.

Benjamin Burnett

Wells Fargo

$48

Buy

21.37%

Upside

Initiated

09/03/25

Xenon (XENE) Receives a New Rating from Wells FargoWells Fargo analyst Benjamin Burnett assumes coverage on Xenon Pharmaceuticals (NASDAQ: XENE) with a Overweight rating and a price target of $48.00.

Brian Abrahams

RBC Capital

$55

Buy

39.06%

Upside

Reiterated

09/02/25

Xenon (XENE) Receives a Buy from RBC Capital

Douglas Tsao

H.C. Wainwright

$53

Buy

34.01%

Upside

Reiterated

08/12/25

Xenon's Promising Pipeline and Strategic Progress Justify Buy Rating

Cory Kasimov

Evercore ISI

$55

Buy

39.06%

Upside

Reiterated

08/12/25

Evercore ISI Reaffirms Their Buy Rating on Xenon (XENE)

Marc Goodman

Leerink Partners

$50

Buy

26.42%

Upside

Reiterated

08/12/25

Xenon: Promising Outlook with Strong Financial Health and Expanding Research InitiativesWe reiterate our Outperform rating and believe that XENE remains a name to own into 2026.

Serge Belanger

Needham

$55

Buy

39.06%

Upside

Reiterated

08/12/25

Xenon Pharmaceuticals: Promising Clinical Developments and Strategic Positioning Support Buy Rating

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

08/11/25

TD Cowen Reaffirms Their Buy Rating on Xenon (XENE)We continue to be optimistic for success based on our KOL feedback and azet's data from the Ph. IIb/OLE. Pipeline also progresses with add'l azet studies in BPD Type I/II and MDD initiated, and Ph. I studies of (Nav1.7) also ongoing. Remain Buy.

Jason Gerberry

Bank of America Securities

$49

Buy

23.89%

Upside

Reiterated

08/11/25

Bank of America Securities Remains a Buy on Xenon (XENE)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$60

Buy

51.71%

Upside

Reiterated

08/11/25

Guggenheim Reaffirms Their Buy Rating on Xenon (XENE)

Tessa Romero

J.P. Morgan

$63→$60

Buy

51.71%

Upside

Reiterated

05/15/25

Xenon Pharmaceuticals (XENE) PT Lowered to $60 at JPMorganJPMorgan analyst Tessa Romero lowered the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $60.00 (from $63.00) while maintaining a Overweight rating.

Charles Duncan

Cantor Fitzgerald

$55

Buy

39.06%

Upside

Reiterated

05/13/25

Cantor Fitzgerald reiterates Overweight Rating on Xenon Pharmaceuticals (XENE)Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating and $55.00 price target on Xenon Pharmaceuticals (NASDAQ: XENE).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Myles Minter

William Blair

―

Buy

―

Reiterated

10/07/25

William Blair Reaffirms Their Buy Rating on Xenon (XENE)

Paul Matteis

Stifel Nicolaus

$60

Buy

51.71%

Upside

Reiterated

10/07/25

Stifel Nicolaus Keeps Their Buy Rating on Xenon (XENE)

Andrew Tsai

Jefferies

$65

Buy

64.35%

Upside

Reiterated

10/07/25

Xenon (XENE) Receives a Buy from Jefferies

Rudy Li

Chardan Capital

$55

Buy

39.06%

Upside

Reiterated

10/07/25

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (NASDAQ: BMEA), Xenon (NASDAQ: XENE) and Arcus Biosciences (NYSE: RCUS)We reiterate our Buy rating and $55 PT.

Benjamin Burnett

Wells Fargo

$48

Buy

21.37%

Upside

Initiated

09/03/25

Xenon (XENE) Receives a New Rating from Wells FargoWells Fargo analyst Benjamin Burnett assumes coverage on Xenon Pharmaceuticals (NASDAQ: XENE) with a Overweight rating and a price target of $48.00.

Brian Abrahams

RBC Capital

$55

Buy

39.06%

Upside

Reiterated

09/02/25

Xenon (XENE) Receives a Buy from RBC Capital

Douglas Tsao

H.C. Wainwright

$53

Buy

34.01%

Upside

Reiterated

08/12/25

Xenon's Promising Pipeline and Strategic Progress Justify Buy Rating

Cory Kasimov

Evercore ISI

$55

Buy

39.06%

Upside

Reiterated

08/12/25

Evercore ISI Reaffirms Their Buy Rating on Xenon (XENE)

Marc Goodman

Leerink Partners

$50

Buy

26.42%

Upside

Reiterated

08/12/25

Xenon: Promising Outlook with Strong Financial Health and Expanding Research InitiativesWe reiterate our Outperform rating and believe that XENE remains a name to own into 2026.

Serge Belanger

Needham

$55

Buy

39.06%

Upside

Reiterated

08/12/25

Xenon Pharmaceuticals: Promising Clinical Developments and Strategic Positioning Support Buy Rating

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

08/11/25

Jason Gerberry

Bank of America Securities

$49

Buy

23.89%

Upside

Reiterated

08/11/25

Bank of America Securities Remains a Buy on Xenon (XENE)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$60

Buy

51.71%

Upside

Reiterated

08/11/25

Guggenheim Reaffirms Their Buy Rating on Xenon (XENE)

Tessa Romero

J.P. Morgan

$63→$60

Buy

51.71%

Upside

Reiterated

05/15/25

Charles Duncan

Cantor Fitzgerald

$55

Buy

39.06%

Upside

Reiterated

05/13/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Xenon

1 Month

xxx

Success Rate

9/16 ratings generated profit

Average Return

+0.78%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.25% of your transactions generating a profit, with an average return of +0.78% per trade.

3 Months

xxx

Success Rate

14/24 ratings generated profit

Average Return

+14.72%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +14.72% per trade.

1 Year

Andrew TsaiJefferies

Success Rate

13/16 ratings generated profit

Average Return

+30.28%

reiterated a buy rating 2 days ago

Copying Andrew Tsai's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +30.28% per trade.

2 Years

xxx

Success Rate

11/16 ratings generated profit

Average Return

+41.01%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 68.75% of your transactions generating a profit, with an average return of +41.01% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XENE Analyst Recommendation Trends

Rating

May 25

Jun 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, XENE has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. XENE average Analyst price target in the past 3 months is 55.00.

Each month's total comprises the sum of three months' worth of ratings.

XENE Financial Forecast

XENE Earnings Forecast

Next quarter’s earnings estimate for XENE is -$1.15 with a range of -$1.27 to -$0.97. The previous quarter’s EPS was -$1.07. XENE beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year XENE has Preformed in-line its overall industry.

XENE Sales Forecast

Next quarter’s sales forecast for XENE is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. XENE beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year XENE has Preformed in-line its overall industry.

XENE Stock Forecast FAQ

What is XENE’s average 12-month price target, according to analysts?

Based on analyst ratings, Xenon Pharmaceuticals’s 12-month average price target is 55.00.

What is XENE’s upside potential, based on the analysts’ average price target?

Xenon Pharmaceuticals has 39.06% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is XENE a Buy, Sell or Hold?

Xenon Pharmaceuticals has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Xenon Pharmaceuticals’s price target?

The average price target for Xenon Pharmaceuticals is 55.00. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $65.00 ,the lowest forecast is $48.00. The average price target represents 39.06% Increase from the current price of $39.55.

What do analysts say about Xenon Pharmaceuticals?

Xenon Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of XENE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Xenon (XENE) Stock Forecast & Price Target

XENE Analyst Ratings

XENE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Xenon

XENE Analyst Recommendation Trends

XENE Financial Forecast

XENE Earnings Forecast

XENE Sales Forecast

XENE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts